Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Ani Pharmaceuticals (ANIP) Long-Term Debt Repayments (2022 - 2024)

Ani Pharmaceuticals' Long-Term Debt Repayments history spans 3 years, with the latest figure at $291.0 million for Q3 2024.

On a quarterly basis, Long-Term Debt Repayments rose 19500.0% to $291.0 million in Q3 2024 year-over-year; TTM through Sep 2024 was $295.5 million, a 39300.0% increase, with the full-year FY2023 number at $3.0 million, changed 0.0% from a year prior.
Long-Term Debt Repayments hit $291.0 million in Q3 2024 for Ani Pharmaceuticals, up from $750000.0 in the prior quarter.
Over the last five years, Long-Term Debt Repayments for ANIP hit a ceiling of $291.0 million in Q3 2024 and a floor of -$1.5 million in Q3 2023.
Historically, Long-Term Debt Repayments has averaged $27.1 million across 3 years, with a median of $750000.0 in 2022.
Biggest five-year swings in Long-Term Debt Repayments: plummeted 300.0% in 2023 and later surged 19500.0% in 2024.
Tracing ANIP's Long-Term Debt Repayments over 3 years: stood at $750000.0 in 2022, then soared by 300.0% to $3.0 million in 2023, then soared by 9600.0% to $291.0 million in 2024.
Business Quant data shows Long-Term Debt Repayments for ANIP at $291.0 million in Q3 2024, $750000.0 in Q2 2024, and $750000.0 in Q1 2024.